Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity

DX-8951f (exatecan mesylate), a new water-soluble derivative of camptothecin, is currently being evaluated in phase II clinical trials. Resistance may be acquired when treating cancer patients with DX-8951f. Therefore, we selected a subline of the human ovarian cancer cell line A2780 for resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hattum, A H, Hoogsteen, I J, Schlüper, H M M, Maliepaard, M, Scheffer, G L, Scheper, R J, Kohlhagen, G, Pommier, Y, Pinedo, H M, Boven, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364245/
https://www.ncbi.nlm.nih.gov/pubmed/12237778
http://dx.doi.org/10.1038/sj.bjc.6600508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364245/
https://www.ncbi.nlm.nih.gov/pubmed/12237778
http://dx.doi.org/10.1038/sj.bjc.6600508

Ejemplares similares